Media

Celebrating Biotech Company of the Year 2025! 🥇!

Awarded Biotech Company of the Year at the Pharma Industry Awards 2025. Celtic also made two other finalists categories including Biopharma Company of the Year & Pharma Industry Company of the Year. Judges Celtic team summary: “They are a true testament of skill, passion and perseverance and deserving of the Biotech Company of the Year!”

We're delighted to announce the shortlist for the coveted Biopharma Company of the Year at the Pharma Industry Awards 2025!

These organisations are at the forefront of biological innovation and sector growth in Ireland:

• AbbVie in Ireland
• Amgen
• Celtic Biotech Ltd
• Takeda UK and Ireland

Celtic Biotech’s Clinical Team Presents Promising Phase I Crotoxin Trial Data at ESMO 2025.

Celtic Biotech’s clinical team recently presented data from their ongoing Phase I clinical trial of Crotoxin in patients with advanced cancer at ESMO 2025 in Berlin. The results demonstrated that the intra-patient dose escalation strategy was both safe and feasible, with a trend toward clinical benefit observed. These findings support the continued progression of the Phase I trial (Cohort III) to determine the recommended dose for further clinical development of Crotoxin.

Ireland’s pharma sector is world class, but why don’t we have a Novo Nordisk to take our success to the next level?

Denmark has Novo Nordisk, France has Sanofi, Switzerland boasts both Roche and Novartis, while Germany has Bayer. It’s a somewhat troubled relationship, but Britain has AstraZeneca. However, Ireland – even though 80,000 people on the island work in the sector – has no pharma giant to call its own.

CB-24 is a therapeutic peptide derived from snake venom. Where does Celtic Biotech get its venom?

Jim and Kristen at Kentucky Reptile Zoo manage our proprietary colony of Crotalus Durrissus. See how they extract the precious venom

Celtic Biotech selected by European Innovation Council to represent best in EU Deep Tech at Dublin Tech Summit 2025

Celtic Biotech and 3 other EIC Accelerators were selected by the European Innovation Council to exhibit and present at the EIC stand at Dublin Tech Summit 2025.

Dr. Dorothy Bray, our Clinical Director, leads the panel discussion on "Bringing Novel Peptide Therapeutics Onto The Market" at NextGen Biomed 2025

Celtic Biotech and 3 other EIC Accelerators were selected by the European Innovation Council to exhibit and present at the EIC stand at Dublin Tech Summit 2025.

Developing a First-in-Class Biologic Targeting the Nicotinic Receptor on Cancer Cells to Trigger Cell Death

CB-24 represents the world's first biologic anti-cancer monotherapy. Currently in Phase I clinical trials, the initial primary disease target will be the deadliest globally non-small cell lung cancer.

The drug by-passes healthy cells leaving patients with mild or no side effects.